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was adapted to the Portuguese setting to evaluate the cost-effectiveness (CEA) of 
linezolid vs.vancomycin in MRSA cSSTI. Methods: Published Bayesian evidence 
synthesis results were used to populate efficacy parameters of the model. Resource 
utilization and MRSA prevalence rates were obtained through an expert panel of 
Portuguese clinicians and costs from published sources were applied to resource 
units. Analyses were done from the Portuguese NHS perspective. Both univariate 
and probabilistic sensitivity analyses were performed to test the robustness of model 
results. Results: Average cost per patient for linezolid and vancomycin treatments 
were 15,195€ and 17,345€ respectively. Average effectiveness gained with linezolid 
treatment was 0.002QALYs. Average saving obtained with linezolid treatment was 
2150€ per patient. ConClusions: Linezolid is a dominant strategy compared to 
vancomycin: less costly and more effective. Compared to vancomycin, linezolid is 
expected to result in lower total costs that offset its higher acquisition cost in cSSTI 
in Portugal.
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objeCtives: To assess the cost-effectiveness of ranibizumab compared to verteporfin 
in photodynamic therapy (vPDT) for the treatment of myopic choroidal neovasculari-
zation (mCNV) from the Canadian health care and societal perspectives. Methods: 
A Markov model was used to follow a cohort of 55-year old patients with mCNV over 
a lifetime horizon. The model included 8 health states based on best corrected visual 
acuity (BCVA) and an absorbing death state. Patients were allowed to remain in their 
current health state, or transition to other health states or death every 3 months. 
Results from the RADIANCE trial were used to inform the first year transitions for 
patients receiving ranibizumab, and the first 3 months for those on vPDT. The VIP 
trial was used to estimate month 4-12 transitions for vPDT. Patients transitioned 
according to natural progression from year 2 onwards. Health state utilities were 
derived from a Canadian utility study and published sources. Resource use and costs 
were collected from clinical trials, published literature, expert opinion, and standard 
Canadian sources. Results: From the health care perspective, patients receiving 
ranibizumab for mCNV incurred less health care costs compared to those on vPDT 
(cost savings of $3,939). This was achieved while accruing an additional 0.07 life years 
(LYs) and 0.37 quality-adjusted life years (QALYs). Thus ranibizumab dominated vPDT. 
Similar findings were observed from the societal perspective (cost saving of $14,217). 
The average BCVA score remained consistently higher with ranibizumab compared to 
vPDT over the entire time horizon. ConClusions: From a cost-effectiveness stand-
point, ranibizumab dominated vPDT in the treatment of mCNV, from both Canadian 
health care and societal perspectives. Patients on ranibizumab realized more QALYs 
and LYs at a lower cost compared to vPDT.
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objeCtives: Monthly dosing with ranibizumab (RBZ) is needed to achieve maxi-
mal sustained visual gains in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In Sweden dosing is on an as-needed (PRN) basis, resulting in 
suboptimal efficacy. Intravitreal aflibercept dosed every 2 months (IVT-AFL) demon-
strated clinically equivalent efficacy compared to RBZ monthly dosing (RBZ Q4) in a 
randomized clinical trial setting. We assessed the cost-effectiveness of IVT-AFL vs. 
RBZ Q4 and RBZ PRN real-life data, in a Swedish setting. Methods: A Markov model 
compared wAMD treatment over two years with either IVT-AFL, RBZ Q4 or real-life 
RBZ PRN. Health states were based on visual acuity in the better-seeing eye; a propor-
tion discontinued treatment monthly or upon visual acuity < 20/400. Parameters were 
estimated from trial data, published literature, or expert opinion. Analyses were per-
formed from a societal perspective with a lifetime horizon (starting age 77 years). The 
model calculated costs (drug, administration, monitoring, vision impairment, adverse 
events, caregiver), quality-adjusted life-years (QALYs), and incremental cost-effec-
tiveness ratios (ICERs), all discounted 3% annually. Deterministic and probabilistic 
sensitivity analyses were performed. Results: IVT-AFL cost 578,400 SEK, compared 
with 686,600 SEK for RBZ Q4 and 565,700 SEK for real-life RBZ PRN; QALYs totaled 4.58 
for IVT-AFL, 4.59 for RBZ Q4, and 4.43 for real-life RBZ PRN. Compared with real-life 
RBZ PRN, IVT-AFL cost 80,000 SEK/QALY gained. RBZ Q4 cost over 20 million SEK/
QALY gained, compared with IVT-AFL Q8. The model was most sensitive to IVT-AFL 
efficacy and patient age. IVT-AFL had a 42% probability of dominating RBZ Q4 and a 
100% probability of being cost-effective vs. RBZ PRN, at an assumed willingness-to-pay 
threshold of 500,000 SEK. ConClusions: Results suggest that, in Sweden, attainment 
of maximal visual gains via IVT-AFL is cost-effective compared with real-life RBZ PRN 
dosing. RBZ Q4 is not cost-effective relative to IVT-AFL.
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objeCtives: To evaluate the cost-effectiveness of bimatoprost 0.03%/timolol 0.05% 
(BTFC) preservative-free (PF) fixed combination compared with dorzolamide/timolol 
costs. Drug acquisition cost for ustekinumab reflected the manufacturers’ UK Patient 
Access Scheme. Incremental cost-effectiveness ratios (ICERs) were calculated and 
treatments were ranked relative to supportive care. One-way sensitivity analyses, 
using alternative plausible values for key parameters, explored uncertainty in the 
results. Results: Infliximab provided the most additional quality-adjusted life-years 
(QALYs) vs. supportive care (0.186) followed by ustekinumab (0.174) and adalimumab 
(0.169). In the base case, adalimumab was the most cost-effective biologic (£19,082/
QALY vs. supportive care), followed by ustekinumab (£20,964/QALY), etanercept 25 mg 
BIW (£26,580/QALY), etanercept 50 mg BIW during the trial period followed by 25mg 
BIW (£28,719 per QALY), and infliximab (£46,844 per QALY). ICERs for ustekinumab 
and infliximab compared with adalimumab were £87,625 and £332,015, respectively. 
Adalimumab remained the most cost-effective in the majority of the sensitivity analy-
ses. ConClusions: In this decision-model analysis, adalimumab was the most cost-
effective biologic treatment for moderate to severe psoriasis in the UK.
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objeCtives: Ingenol mebutate gel is a recently developed, topical, 2 or 3 days patient-
administered AK therapy. The objective was to compare the cost-effectiveness of ingenol 
mebutate gel with diclofenac gel and other available therapies for the first-line treat-
ment of AK in adult patients, from the perspective of the National Health Service (NHS) 
in Scotland. Methods: A cost-utility analysis was conducted using a decision tree 
approach to calculate the costs and benefits of different treatment strategies for AK over 
a 12-month time horizon. Data on the relative efficacy of treatment was derived from a 
systematic review of RCTs and a subsequent mixed-treatment comparison (MTC). Utility 
scores and resource use data were obtained from published sources. Due to the uncer-
tainty surrounding the impact of AEs on HRQoL and costs, AEs were modelled in a sce-
nario analysis. Results: In the primary comparison, ingenol mebutate 150 mcg/g gel and 
500 mcg/g gel were associated with ICERs of £44 and £114 per QALY gained, respectively 
compared with diclofenac (3%) for 8 weeks and £36 and £74, respectively compared with 
diclofenac (3%) for 12 weeks. In the secondary comparisons, ingenol mebutate 150 mcg/g 
gel and 500 mcg/g gel were associated with ICERs of £47 and £134, respectively compared 
with 5-FU/salicylic acid (0.5%/10%) cutaneous solution and dominated cryotherapy (i.e. 
were cheaper and more effective). Ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were 
cheaper and less effective than 5-FU (5%) cream. Ingenol mebutate 150 mcg/g gel, but not 
ingenol mebutate 500 mcg/g gel, was cost-effective assuming a decision making will-
ingness-to-pay threshold of £20,000/QALY (for one additional QALY gained, there would 
be an incremental cost of £26,525 incurred for 5-FU (5%) cream vs ingenol mebu-
tate gel). ConClusions: Ingenol mebutate gel is a fast-acting, convenient 
and, relative to most comparators, cost-effective therapy for the first-line treatment 
of AK.
PSS25
coSt EffEctivEnESS of anti-oxidant vitamin + zinc tREatmEnt to 
PREvEnt thE PRogRESSion of intERmEdiatE agE RElatEd maculaR 
dEgEnERation to itS wEt foRm. a SingaPoRE PERSPEctivE
Saxena N.1, George P.P.1, Heng B.H.1, Lim T.H.2, Yong S.O.2
1National Healthcare Group, Singapore, Singapore, 2Tan Tock Seng Hospital, Sinapore, Singapore
objeCtives: To determine if providing high dose anti-oxidant vitamins + Zinc 
treatment to intermediate Age Related Macular Degeneration (AMD) patients 
aged 40-79 years from Singapore is cost effective in preventing progression to Wet 
AMD. Methods: We estimated the number of AMD patients aged 40 to 79 years 
(Category 3 and 4) in the Singaporean resident population. This hypothetical cohort 
was followed for 5 calendar years to determine the number of patients who would 
progress to wet AMD given the following four treatment scenarios: a) Vitamins 
+Zn followed by Ranibizumab (as needed) for wet AMD; b) Placebo followed by 
Ranibizumab (as needed) for wet AMD; c) Vitamins + Zn followed by Bevacizumab 
(monthly) for wet AMD; and d) Placebo followed by Bevacizumab (monthly) for wet 
AMD. Costs were estimated for the above scenarios from the providers’ perspective 
and cost effectiveness was measured by cost per disability adjusted life year (DALY) 
averted with a disability weight of 0.22 for wet AMD. Crude annual mortality rate 
was incorporated into the model. Results: Over 5400 patients could be prevented 
from progressing to Wet AMD cumulatively over five years if preventive anti-oxidant 
vitamins +Zn treatment were prescribed. Vitamins + Zn followed by ranibizumab 
(as needed) or bevacizumab (monthly) was cost effective compared to placebo fol-
lowed by either drug (cost per DALY averted: $1885.8 - well within the threshold 
suggesting it is cost effective). However, bevacizumab (monthly 1 injection) alone 
was cost effective. Cost savings as a result of prescribing anti-oxidant vitamins +Zn 
were $ 46.7M for ranibizumab arm over 5 years. ConClusions: Prophylactic treat-
ment with high dose anti-oxidant vitamins + Zn for intermediate AMD patients, 
followed by ranibizumab for patients who progressed to wet AMD was found to be 
cost-effective. These findings have implications for intermediate AMD screening, 
treatment and health care planning in Singapore.
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objeCtives: Methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infection (cSSTI) is an infection associated with high health expendi-
ture for the Portuguese National Health Service (NHS). A decision analytic model 
